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Abstract
Background: Multiple micronutrient supplementation for pregnant women reduces low birth weight and has
been recommended in low- and middle-income countries (LMICs) to improve child survival, growth and health.
We aimed to review the evidence from long-term follow-up studies of multiple micronutrient supplementation
beginning in the later first or second trimester.
Methods: We searched systematically for follow-up reports from all trials in a 2015 Cochrane review of multiple
micronutrient supplementation in pregnancy. The intervention comprised three or more micronutrients and the
comparison group received iron (60 mg) and folic acid (400 μg), where possible. Median gestation of commencement
varied from 9 to 23 weeks. Primary outcomes were offspring mortality, height, weight and head circumference,
presented as unadjusted differences in means or proportions (intervention minus control). Secondary outcomes
included other anthropometry, body composition, blood pressure, and cognitive and lung function.
Results: We found 20 follow-up reports from nine trials (including 88,057 women recruited), six of which used the
UNIMMAP supplement designed to provide recommended daily allowances. The age of follow-up ranged from 0 to
9 years. Data for mortality estimates were available from all trials. Meta-analysis showed no difference in mortality
(risk difference –0.05 per 1000 livebirths; 95 % CI, –5.25 to 5.15). Six trials investigated anthropometry and found
no difference at follow-up in weight-for-age z score (0.02; 95 % CI, –0.03 to 0.07), height-for-age z score (0.01;
95 % CI, –0.04 to 0.06), or head circumference (0.11 cm; 95 % CI, –0.03 to 0.26). No differences were seen in body
composition, blood pressure, or respiratory outcomes. No consistent differences were seen in cognitive function scores.
Conclusions: There is currently no evidence that, compared with iron and folic acid supplementation, routine maternal
antenatal multiple micronutrient supplementation improves childhood survival, growth, body composition, blood
pressure, respiratory or cognitive outcomes.
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Background
Micronutrient deficiency is believed to affect approximately
two billion people worldwide, with pregnant women being
at particular risk because of their high metabolic demands
[1]. The World Health Organization (WHO) considers
micronutrient deficiency to be of particular concern in
low-income countries, where women’s diets are likely
to be deficient in both quantity and quality. The im-
portance of micronutrients is becoming increasingly
apparent, especially in resource-poor settings in which
women may enter pregnancy with multiple micronu-
trient (MMN) deficiencies [2–4]. For example, 38 % of
pregnant women have iron deficiency leading to anaemia
[5] and 15 % have vitamin A deficiency causing night blind-
ness and increasing the risk of infection [6, 7]. Impaired
antenatal nutrition can affect fetal development and growth
in the short term, subsequent growth and cognitive devel-
opment in the medium term, and risk of chronic disease in
the longer term [3]. There is good evidence that folic acid
in pregnancy reduces neural tube defects and the mortality
arising from them [8, 9]. While the evidence base is not
substantial for iron and folic acid, a Cochrane review de-
scribed a mean increase in birthweight of 57.7 g (95 % CI,
7.7–107.8 g) [10].
While there is evidence that MMN supplementation
reduces the prevalence of small for gestational age (SGA)
births [11], the primary rationale for recent recommenda-
tions to implement routine MMN supplementation for
pregnant women in developing countries is that such birth
weight increments will lead to reductions in childhood
stunting and mortality [12, 13]. In addition to the immedi-
ate effects on health, growth in early childhood is important
because of its association with adult health and human cap-
ital [14]. The hypothesis of the developmental origins of
health and disease proposes critical or sensitive periods in
early development in which environmental influences can
have lasting effects on growth and physiology [15]. In
humans, these critical periods are thought to occur pre-
dominantly in prenatal life and extend into early childhood.
Suggested mechanisms include an interplay between envir-
onment (including maternal nutritional status), genes, and
hormones, in which epigenetic regulation plays a part
[3, 15, 16]. Evidence for the hypothesis comes mainly from
observational studies showing associations between low
birthweight and adverse adult health outcomes [17], from
historical events such as the Dutch Hunger Winter [18],
and from animal studies [19]. Long-term follow-up of chil-
dren born during trials of maternal MMN supplementation
offer a potentially stronger test of the hypothesis. If MMN
supplements are to be recommended for pregnant women,
it is important to know whether they lead to the sustained
improvements in child health predicted by an increase in
birthweight. In this review, we searched for reports that
followed up the trials included in the 2015 Cochrane review
[20], focusing on childhood mortality and health-related
outcomes (growth, body composition, cardio-metabolic risk
markers, cognition, lung function). We hypothesized that,
compared with iron and folic acid, antenatal MMN supple-
mentation would lead to longer-term improvements in
health and survival.
Methods
Eligibility criteria
Types of report
We attempted to find all reports of follow-up of children
born in the individual or cluster randomized controlled
trials included in the 2015 Cochrane review. The review
included 17 trials and excluded 97. The main reasons for
exclusion were not meeting intervention and comparison
group criteria, not assessing supplementation in a healthy
population, and providing supplementation within food
fortification initiatives [20].
Participants
Participants were children born in the trials in the
2015 Cochrane review [20] who had been subsequently
followed up.
Intervention and comparison groups
The intervention group included women who had re-
ceived multiple micronutrient supplements, defined as
“containing three or more micronutrients” in pregnancy
[20]. All intervention groups received iron and folic acid.
For consistency, the comparison group chosen a priori
was iron 60 mg and folic acid 400 μg, where possible, as
this regimen is generally recommended for pregnant
women [21]. We planned to consider all trials together,
with the possibility of subgroup examination when
supplementation regimens differed. Trials with co-
interventions (for example, food supplements) were
eligible provided that the co-intervention was similar
in both allocation arms. If a second randomization
was conducted after birth, we did not include arms that
received MMN supplements in the comparison group.
Outcome measures
The primary outcomes were mortality (difference per
1000 livebirths), height and weight (as continuous WHO
z scores, adjusted for age and sex), and head circumfer-
ence (continuous difference), presented as unadjusted
differences (intervention minus control). At a population
level, risk differences may be more interpretable than
odds ratios because they give a clearer impression of the
effects of an intervention in terms of potential policy.
When not reported, we calculated mean differences with
95 % confidence intervals. Mortality difference was either
as described in the trial paper or follow-up report, or cal-
culated from available trial profiles. Secondary outcomes
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included categorical proportions of stunting (< –2 z scores
height-for-age), underweight (< –2 z scores weight-for-
age), wasting (< –2 z scores weight-for-height) and low
body mass index (BMI) (< –2 z scores BMI-for-age),
descriptions of body composition (lean and fat mass,
skinfold thickness), blood pressure, cognitive tests, and
lung function. Cognitive and motor development were
as assessed by trialists, including use of indexes such as the
Bayley Mental Development Index, Bayley Psychomotor
Development Index, Stanford-Binet Test, DENVER II
Developmental Screening Test and Wechsler Intelligence
Scale for Children. Effect modification by maternal nutri-
tional status and child sex was reported when available.
Birth outcomes were not considered as they had been
reported previously [11, 22].
Search strategy and study selection
We searched PubMed, Web of Science and the Global
Health Library for articles that included trial lead author
names, location, trial number, or the given trial name
(Additional file 1: Text S1). We contacted trial authors
when eligibility was unclear and used a snowballing
approach, searching citation lists and ‘related articles’.
Study titles and abstracts were screened for eligibility by
DD and JCKW independently. Differences were resolved
by discussion. Full papers were obtained for potentially
eligible citations. The results were assessed for multiple
publications and one study was excluded. We did not as-
sess reports of maternal outcomes. No exclusions were
applied for age, dates of coverage, or language.
Data extraction and analysis
Publications from each trial were examined by two re-
view authors (unconnected with the trial) independently
(AC, BM, CHDF, DD, DO, HSS, and JCKW), using a
pre-tested data extraction form. Differences were resolved
by discussion. We contacted trial authors for clarifications
and consolidated multiple reports from the same trial
using data from the later follow-up. We used anthropo-
metric z scores adjusted for age and sex (WHO reference
ranges). Meta-analyses were conducted if sufficient reports
were available, using the DerSimonian and Laird model.
When numbers of deaths were provided for a sub-
group of participants in a second age interval, we com-
bined the data to produce an estimate of the mortality
rate across both intervals using standard life-table tech-
niques, and generated 95 % confidence intervals through
a simulation approach. Outcome measures were risk dif-
ferences per 1000 livebirths (mortality), differences in an-
thropometry z scores (height-for-age (HAZ) and weight-
for-age (WAZ)) and absolute values (head circumference
and blood pressure). We assessed heterogeneity using the
I2 statistic. In view of anticipated contextual heterogeneity,
we used a random effects model for all meta-analyses.
Missing data were reported under attrition bias, but no
further analyses were conducted. For cluster-randomised
trials, we used reported cluster-adjusted estimates, irre-
spective of the method employed. If the analyses had
not been adjusted for cluster design effect, we used a
previously reported design effect from the trial paper to
inflate the variance. Analysis was conducted in Stata,
version 12 (StataCorp, College Station, TX, USA).
Risk of bias
Risk of bias for each study was assessed by two review
authors (unconnected with the trial) independently
(AC, BM, CHDF, DD, DO, HSS, and JCKW), using a
pre-tested data extraction form. Differences were re-
solved by discussion and trial authors were contacted for
clarifications. We used the same categorisation of bias of
individual trials as in the Cochrane review 2015. We re-
ported on bias in follow-up reports in the following cat-
egories: selection, attrition, reporting, performance and
detection. We evaluated reporting bias by inspection of
funnel plots for the primary outcomes of mortality,
weight-for-age, height-for-age and head circumference.
Sub-group analysis
We performed sub-group analyses including trials that
used UNIMMAP only and trials with different iron dos-
age (~30 or 60 mg) in control groups. Sensitivity ana-
lyses were not conducted.
Results
Description of trials with follow-up reports
Follow-up reports were identified for nine of the trials in
the Cochrane review. In total, 88,057 women were re-
cruited. The trials were spread geographically: two in Af-
rica [23, 24], one in the Americas [25], and six in Asia
[26–31]. All sites were rural, with the exception of Nepal
Janakpur (urban and rural) and Guinea (semi-urban).
Mean ages of mothers were similar and ranged from
21.5 (Nepal Janakpur) to 25.6 years (Indonesia). Mean
maternal BMI, measured at recruitment during pregnancy,
ranged from 19.3 kg/m2 (Nepal Sarlahi) to 24.1 kg/m2
(Mexico). Trial characteristics, with results summarized in
the way in which they were presented in the trial papers,
are shown in Table 1 and have been previously described
in detail [20, 32].
Six of the nine trials used the UNIMMAP supplement
developed by UNICEF, the United Nations University,
and WHO, and were designed to provide the recom-
mended daily allowances. It contained vitamin A 800 μg,
thiamine 1.4 mg, riboflavin 1.4 mg, niacin 18 mg, vitamin
B6 1.9 mg, folic acid 400 μg, vitamin B12 2.6 μg, vitamin
C 70 mg, vitamin D 5 μg, vitamin E 10 mg, copper 2 mg,
iodine 150 μg, iron 30 mg, selenium 65 μg, and zinc
15 mg [33]. The Bangladesh JiVitA trial used the same
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Table 1 Description of trials with follow-up reports
Location Trial Randomisation
scheme
Pregnant women
allocated (MMN and
Fe60 Fol groups only)
Mean duration from
LMP to beginning of
supplementation and
when supplementation
stoppeda
Control content Intervention contentb Mean maternal BMI
(kg/m2)
Main results from original trial
paper (intervention effect
relative to comparison group)
Bangladesh
JiVitA
West et al. [26] Cluster 127,282 women
under pregnancy
surveillance; 44,567
pregnancies recruited
in 596 clusters
Median at enrolment
9 weeks until 12 weeks
after birth
Iron 27 mg, folic
acid 600 μg
Vit A, thiamine,
riboflavin, vit B3, vit B6,
folic acid, B12, vit C,
vit D, vit E, copper,
iodine, iron, selenium,
zinc
Mean BMI unknown;
proportion < 18.5 40 %
Birthweight, + 54 g (95 % CI,
41–66 g)
SGA RR, 0.98 (95 % CI,
0.96–1.01)
Gestation, 0.30 weeks (95 % CI,
0.21–0.40 weeks)
Neonatal mortality RR, 0.98
(95 % CI, 0.88–1.20)
Bangladesh
MINIMat
Persson
et al. [27]
Individual 1478 102 days until birth Iron 60 mg, folic
acid 400 μg and
“usual” food
supplementation
UNIMMAP and “usual”
food supplementation
20.3 Birthweight in MMN, 2710 g
(95 % CI, 2675–2745 g)
Birthweight in control, 2665 g
(95 % CI, 2631–2699 g)
Gestation in MMN, 39.1 weeks
(95 % CI, 38.9–39.3 weeks);
gestation in control, 38.8 weeks
(95 % CI, 38.6–39.0 weeks)
Perinatal mortality RR, 0.95
(95 % CI, 0.59–1.5)
Neonatal mortality RR, 1.1
(95 % CI, 0.64–2.0)
Burkina Faso Roberfroid
et al. [23]
Individual 1428 125 days until
3 months after birth
Iron 60 mg, folic
acid 400 μg
UNIMMAP; also
randomly assigned to
receive either
chloroquine 300 mg
weekly or sulfadoxine
1500 mg and
pyrimethamine 75 mg
once in 2nd and 3rd
trimesters as malaria
chemoprophylaxis
20.9 Birthweight, + 41 g (95 % CI,
–11 to 94 g), adjusted for
malaria prevention and health
centre
SGA, 0.83 (95 % CI, 0.65–1.07),
adjusted for malaria prevention
and health centre
Gestation, –0.04 weeks (95 % CI,
–0.38 to 0.29 weeks), adjusted
for malaria prevention and
health centre
Perinatal mortality OR, 1.78
(95 % CI, 0.95–3.32)
Neonatal mortality OR, 2.1
(95 % CI, 0.78–5.64)
China Zeng et al. [28] Cluster 3811 women in
104 clusters
96 days until birth Iron 60 mg, folic
acid 400 μg
UNIMMAP 20.9 Birthweight in MMN, 3198 g;
birthweight in control, 3174 g
SGA in MMN, 16.9 %; SGA in
control, 18.9 %
Gestation in MMN, 39.8 weeks;
gestation in control, 39.8 weeks
PMR in MMN group, 50.9; PMR
in control group, 36.9
NMR in MMN group, 12.4;
NMR in control group, 10.7
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Table 1 Description of trials with follow-up reports (Continued)
Guinea Bissau Kaestel
et al. [24]
Individual 1403 158 days until birth Iron 60 mg, folic
acid 400 μg
UNIMMAP; if
haemoglobin
concentration < 70
g/L, given additional
iron 60 mg daily; all
women received
insecticide-treated
bednets, weekly anti
malarial prophylaxis
and malaria treatment
if needed
23.3 Birthweight, + 53.0 g (95 % CI,
–19 to 125 g)
Perinatal mortality OR, 0.82
(95 % CI, 0.53–1.26)
Neonatal mortality OR, 1.18
(95 % CI, 0.66–2.11)
Indonesia Shankar
et al. [29]
Cluster 31,290 women, 262
randomly assigned
midwives
146 days until 90 days
after birth
Iron 30 mg, folic
acid 400 μg
UNIMMAP Not recorded Birthweight, + 21 g (95 % CI,
–11 to 53 g)
Perinatal mortality RR, 0.90
(95 % CI, 0.79–1.03)
Neonatal mortality RR, 0.90
(95 % CI, 0.76–1.06)
Mexico Ramakrishnan
et al. [25]
Individual 873 children born
in the trial were
subsequently
randomised to
receive postnatal
multiple
micronutrients or
iron and vitamin A
supplements
69 days until birth Iron 60 mg; no
supplements on
Sundays
Vit A, thiamine,
riboflavin, niacin, vit B6,
folic acid, vit B12, vit C,
vit D3, vit E, iron,
magnesium, zinc; no
supplements taken on
Sundays
24.1 Birthweight in MMN, 2981 g;
birthweight in control, 2977 g
SGA in MMN, 10.1 %; SGA in
control, 11.8 % Gestation in
MMN, 39.5 weeks; gestation in
control, 39.6 weeks
Nepal Janakpur Osrin et al. [30] Individual 1200 112 days until birth Iron 60 mg, folic
acid 400 μg
UNIMMAP; if
haemoglobin
concentration < 70
g/L, given extra iron
60 mg daily and
anthelminthic
treatment; if
symptoms of night-
blindness, vitamin A
2000 μg
19.9 Birthweight, + 77 g (95 % CI,
24–130 g)
Gestation, 0.2 weeks (95 % CI,
–0.1 to 0.4 weeks)
PMR in MMN, 49.0; PMR in
control, 40.5
NMR in MMN, 30.6; NMR in
control, 20.0
Nepal Sarlahi Christian
et al. [34]
Christian
et al. [31]
Cluster 14,036 women under
pregnancy
surveillance; 2007
pregnancies recruited
in 169 clusters
80 days until 12 weeks
after birth
Iron 60 mg, folic
acid 400 μg, Vit A
1000 μg
Vit A, thiamine,
riboflavin, vit B3, vit B6,
folic acid, vit B12, vit C,
vit D, vit E, vit K,
copper, iron as ferrous
fumerate, magnesium
and zinc; albendazole
was offered in 2nd
and 3rd trimesters
19.3 Birthweight in MMN, 2659 g;
birthweight in control, 2652 g
SGA in MMN, 53.8 %; SGA in
control, 51.7 %
PMR in MMN group, 87.1;
PMR in control group, 62.4
NMR in MMN group, 54.0;
NMR in control group, 36.3
aData from Margetts et al. [32]
bSee Additional file 1: Table S1 for supplement constituents
BMI body mass index, Fe60 Fol iron 60 mg and folic acid supplement, LMP last menstrual period, MMN multiple micronutrient supplement, NMR neonatal mortality per 1000 livebirths, PMR perinatal mortality per 1000
livebirths, RR relative risk, SGA small for gestational age, UNIMMAP United Nations International Multiple Micronutrient Preparation
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micronutrients as UNIMMAP in similar doses. The sup-
plement used in Nepal Sarlahi contained micronutrients
in similar doses (with 60 mg iron), plus magnesium
and vitamin K, but no selenium or iodine [34]. The
supplement used in Mexico included iron 62.4 mg and
magnesium 252 mg, and did not include copper, iodine or
selenium [25]. In some cases, a comparison group of iron
60 mg and folic acid 400 μg was not available: Nepal
Sarlahi included additional vitamin A [34], Mexico did
not include folic acid [25], Indonesia used 30 mg iron [29],
and Bangladesh JiVitA used 27 mg iron and 600 μg folate
[26]. Supplement constituents are shown in Additional file
1: Table S1. Supplementation was initiated in early to mid-
pregnancy, with a range of median commencement gesta-
tion across studies of 14 weeks (Table 1).
Follow-up reports
We found 20 follow-up reports (Table 2 and Additional
file 1: Figure S1). We divided the findings into five gen-
eral categories: mortality [26, 27, 35–41], anthropometry
[35, 38, 39, 41–44] and body composition [39, 44, 45],
cardiovascular [39, 43, 46, 47], cognitive [37, 48–51], and
respiratory [52]. Primary publications from the Bangladesh
JiVitA and MINIMat trials included follow-up mortality
data and were included in the list of follow-up reports.
Meta-analyses were conducted for mortality, weight, height,
head circumference and blood pressure outcomes.
Mortality
Follow-up reports from all trials systematically recorded
and reported infant/child mortality as an outcome (Table 3).
Meta-analysis showed no difference between intervention
and control groups (risk difference, –0.05 per 1000 live-
births; 95 % CI, –5.25 to 5.15; I2, 8 %; Fig. 1). No difference
by age was seen. Subgroup analysis including trials that
used only the UNIMMAP supplement showed a risk differ-
ence of 3.41 per 1000 livebirths (95 % CI, –4.45 to 11.26; I2,
0 %; Additional file 1: Figure S2). Subgroup analysis for
trials that used 60 mg iron in control groups yielded a
risk difference of 4.51 per 1000 livebirths (95 % CI, –2.91
to 11.94; I2, 0 %), and trials that used approximately 30 mg
iron in the control group yielded a risk difference of 0.41
per 1000 livebirths (95 % CI, –14.76 to 15.57; I2, 62 %;
Additional file 1: Figure S3).
Anthropometry
Seven reports described anthropometry (Table 4). No
differences were seen in any report at the most recent
follow-up for WAZ, HAZ or head circumference, nor in
any secondary anthropometric outcomes. Differences were
seen at younger ages in two trials. In the Burkina Faso
trial, greater mean WAZ (β, 0.13; 95 % CI, 0.04 to 0.23)
and length-for-age z score (β, 0.13; 95 % CI, 0.02 to 0.24)
were seen in the multiple micronutrient supplement
group, and a lower proportion were stunted at 1 year (haz-
ard ratio, 0.73; 95 % CI, 0.60 to 0.87), but there was no dif-
ference at 2.5 years of age [35]. In the Nepal Janakpur trial,
greater mean WAZ (β, 0.14; 95 % CI, 0.00 to 0.27) was
seen in the multiple micronutrient supplement group at a
mean of 2.5 years, but there was no difference at 8.5 years
(β, 0.05; 95 % CI, –0.09 to 0.19). Small increases were seen
in head, chest, hip, and mid-upper arm circumferences at
2.5 years, but were also not present at 8.5 years [39, 43].
Effect modification by maternal BMI or child sex
was not found in any report with the exception of the
Bangladesh MINIMat trial, in which stunting was greater in
boys in the MMN group (Males, 7.8 %; 95 % CI, 2.0 to 13.6;
Females, 1.8 %; 95 % CI, –3.8 to 7.3). A test for interaction
was not reported.
Meta-analyses for WAZ and HAZ showed no differ-
ence between multiple micronutrient and 60 mg iron
and folic acid groups. The differences in WAZ and HAZ
were 0.02 (95 % CI, –0.03 to 0.07; I2, 0 %; Fig. 2) and
0.01 (95 % CI, –0.04 to 0.06; I2, 0 %; Fig. 3), respectively.
Meta-analysis for head circumference was possible for three
trials (Mexico, Bangladesh MINIMat and Nepal Janakpur)
and showed no difference (0.11 cm; 95 % CI, –0.03 to 0.26;
I2, 0 %; Fig. 4). Subgroup analysis including UNIMMAP
trials made little difference: WAZ 0.04 (95 % CI, –0.01
to 0.09; I2, 0 %), HAZ 0.01 (95 % CI, –0.05 to 0.06; I2,
0 %), and head circumference 0.11 cm (95 % CI, –0.05
to 0.26; I2, 10 %; Additional file 1: Figure S2).
Body composition
The Bangladesh MINIMat trial found no difference in
biceps, triceps, subscapular or suprailiac skinfold thick-
nesses. The Nepal Janakpur trial found an increase in
triceps skinfold thickness at 2.5 years (0.20 mm; 95 %
CI, 0.00 to 0.40 mm) [43], but no difference was found
in any skinfold thickness at 8.5 years [39]. The Nepal
Sarlahi trial found no difference in triceps or subscapular
skinfold thickness at 7.5 years of age. Neither the
Bangladesh MINIMat nor the Nepal Janakpur trial found
a difference in lean mass or fat mass measured using
bio-impedance [39, 45, 53, 54].
Cardiovascular risk markers
Cardiovascular outcomes were only examined in trials
from South Asia (Table 4). The Bangladesh MINIMat and
Nepal Janakpur trials measured blood pressure, while the
Nepal Sarlahi trial investigated metabolic syndrome (blood
pressure, HbA1c, urine microalbumin:creatinine, choles-
terol, glucose, insulin, homeostasis model assessment of
insulin resistance). The Nepal Janakpur cohort showed a
reduction in mean systolic blood pressure of 2.5 mmHg
(95 % CI, 0.47 to 4.55) at 2.5 years of age, but no difference
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Table 2 Description of follow-up reports
Location Follow-up study Age at follow- up Eligibility/exclusion
criteria for follow-up
Risk of bias in loss to
follow-up
% follow-up in control
groupa
% follow-up in
intervention groupa
Outcome measures
Bangladesh
JiVitA
West et al. [26] 6 months None reported 5 infants lost to follow-up;
assumed to be alive at
180 days
100 % 100 % Mortality assessed at 1, 3
and 6 months
Bangladesh
MINIMat
Persson et al. [27] 5 years None reported None No reported losses No reported losses Mortality assessed at
5 years
Khan et al. [42] 54 months (monthly
to 1 year
3 monthly to 2 years)
Singletons None; imputation used for
missing data points
79.9 % of livebirths;
86.5 % of children with
birth anthropometry
78.3 % of livebirths;
87.9 % of children with
birth anthropometry
Length or height, weight
Khan et al. [45] 54 months Singletons with birth
anthropometry
Children lost more likely to
be first born and have lower
birthweight
72.3 % children with
birth anthropometry
70.9 % children with
birth anthropometry
Mid-upper arm
circumference, skinfold
thickness, body composition
by bioelectrical impedance
Tofail et al. [48] 7 months Subgroup of singletons
born May 2002 to
December 2003
Small but significant
differences in children lost
to follow-up; mothers had
fewer children, higher
haemoglobin and shorter
gestation; no significant
difference in these between
allocation groups
Unable to calculate as
the number of deaths
is only provided for all
allocation groups
combined
Unable to calculate as
the number of deaths is
only provided for all
allocation groups
combined
Cognition (‘Support test’ and
‘Cover test’)
Motor development
(Psychomotor Developmental
Index of Bayley Scales of
Infant Development)
Behaviour (modified Wolke
in three domains: activity,
emotion and vocalization)
Hawkesworth
et al. [46]
4 years (mean
4.6 years)
Singletons born at term
with birth anthropometry
Children lost to follow-up
more likely to have been
firstborn and their mothers
on average ~9 months
younger with 6 months
longer education
69.1 % of livebirths;
73.6 % of children with
birth anthropometry
67.9 % of livebirths;
74.0 % of children with
birth anthropometry
Blood pressure, kidney size
by ultrasound (restricted to
individuals born during the
second half of MINIMat
trial, June 2003 to June 2004),
and glomerular filtration rate
(restricted to individuals born
during first y of MINIMat trial,
June 2002 to June 2003)
Burkina Faso Roberfroid
et al. [35]
Monthly to 12 months
and 30 months
Singletons None 97.8 % 98.0 % Length, weight, head, chest
and mid-upper arm
circumference
China Wang et al. [41] 3 monthly to
12 months, 6 monthly
to 30 months
Subgroup born in middle
year of 3.5 years
recruitment; congenital
disease excluded (n = 3)
Not specified 84.9 % of selected
subgroup
81.3 % of selected
subgroup
Length, weight
Li et al. [49] 3 monthly to 1 year Subgroup born in
middle year of 3.5 years
recruitment
Small difference in Apgar
scores
89.7 % of selected
subgroup
88.6 % of selected
subgroup
Cognition
Mental and Psychomotor
development (Bayley Scales
of Infant Development)
Li et al. [50] 7–9 years Singletons; children who
moved away were
excluded
None 61.0 %b 60.7 %b Cognition
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Table 2 Description of follow-up reports (Continued)
Mental development
(Wechsler Intelligence Scale
for Children)
Guinea Bissau Andersen
et al. [36]
0–2 years None reported Lost to follow-up different
for maternal weight, age,
height and parity; no
difference between trial
groups
77.1 % 77.8 % Mortality by routine
surveillance every 3 months
up to 1 year and every
6 months after 1 year
Indonesia Prado et al. [37] 42 months 2369 of 41,839 women
enrolled randomly
assigned to blood tests;
children of 549 of these
women who gave birth
in a 6 month period
None reported 94.5 % of selected
subgroup
92.8 % of selected
subgroup
Cognition
Adapted, validated tests for
motor, language, visual
attention/spatial, executive
and socio-emotional
function; adjusted analyses
presented: confounders
included ‘home observation
and measurement of
environment’ inventory
score, child haemoglobin,
mother’s mid-upper arm
circumference, birth weight,
MMN adherence
Mexico Ramakrishnan
et al. [38]
3 months
24 months
Singletons; children
from antenatal trial
subsequently
randomised to receive
MMN or iron + Vit A
Lost to follow-up younger
mothers, more educated
and less parous
24.9 % of livebirths in
childhood
randomisation control
group; 69.3 % of
children randomised in
childhood control
26.2 % of livebirths in
the childhood
randomisation MMN
group; 74.2 % of
children randomised in
childhood control
Height, weight, head
circumference
Nepal Janakpur Vaidya et al. [43] 2–3 years None reported Difference in lost to follow-
up in maternal education,
urban/rural residence and
main household occupation
85.8 % 86.5 % Height, weight, head, chest,
waist, hip and mid-upper
arm circumferences, skinfold
thickness, blood pressure
Devakumar
et al. [39]
7–9 years None reported Small difference in lost to
follow-up in maternal
education and urban/rural
residence
80.5 % 79.2 % Height, weight, body
composition by bioelectrical
impedance, skinfold
thickness, head, chest, waist,
hip, mid-upper arm and
upper leg circumferences,
kidney dimensions, blood
pressure
Devakumar
et al. [52]
7–9 years None reported Small difference in lost to
follow-up in maternal
education and urban/rural
residence; small number
(n = 5) with learning
difficulties unable to
complete spirometry
80.5 % 79.2 % Spirometry, respiratory
illness, asthma
D
evakum
ar
et
al.BM
C
M
edicine
 (2016) 14:90 
Page
8
of
20
Table 2 Description of follow-up reports (Continued)
Nepal Sarlahi Stewart et al. [44] 6–8 years 3669 also in subsequent
childhood trial of iron,
folic acid and zinc
Lost to follow-up more
likely to be of Pahadi (hill)
ethnicity, have a literate
mother and own a radio,
and less likely to own cattle
89.2 % 91.2 % Height, weight, mid-upper
arm circumference, waist
circumference, skinfold
thickness
Stewart et al. [47] 6–8 years 3673 also in subsequent
childhood trial of iron,
folic acid and zinc
Loss to follow-up did not
differ between groups;
large number did not
complete all tests; children
with missing data less likely
to be of Pahadi ethnicity or
to have had any schooling,
and had slightly lower BMI
Overall 84.1 %; number
of participants varied
for each test or
measurement
Overall 85.1 %; number
of participants varied for
each test or measurement
Metabolic syndrome
BMI, waist circumference,
blood pressure, HbA1c, urine
microalbumin:creatinine,
cholesterol, glucose, insulin,
homeostasis model
assessment
Christian et al. [51] 7–9 years In control group of
subsequent iron and zinc
pre-school trial; children
followed up in this study
represent 23 % of live
births in relevant
allocation groups in the
original trial
Main loss to follow-up was
exclusion of children taking
part in postnatal supple
mentation trial; children lost
more likely to be of Pahadi
ethnicity, literate mother,
own a radio and less likely
to own cattle
75.2 % of subgroup 84.2 % of subgroup Cognition
Universal Non-verbal
Intelligence Test Movement
Assessment Battery for
Children
Finger-tapping test
Executive Function (Stroop
Numbers Test, backward
digit span, go/no-go)
Environment (Middle
Childhood Home
Observation for the
Measurement of the
Environment inventory)
Maternal intelligence
(Raven Coloured Progressive
Matrices)
Christian et al. [40] 6–8 years None reported None reported 96.1 % 96.0 % Mortality
aDefined as total number measured as a proportion of the total number available for measurement (livebirths minus deaths), as a percentage
bThe percentage excludes 1643 families who have moved out of the area
MMN multiple micronutrient supplement
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at 8.5 years (0.02 mmHg; –1.02 to 1.05) [39, 43]. The
Bangladesh MINIMat cohort showed no difference at
4.5 years compared with a control group who received
iron 30 mg and folic acid [46]. The Nepal Sarlahi trial
found neither a difference in blood pressure at 7.5 years,
nor a difference in other cardiovascular risk markers com-
pared with a control group who received iron 60 mg and
folic acid [47]. Meta-analysis of the three trials showed no
difference in blood pressure: the difference in systolic
blood pressure was 0.11 mmHg (95 % CI, –0.41 to 0.63; I2,
0 %), and in diastolic pressure 0.47 mmHg (95 % CI, –0.01
to 0.95; I2, 0 %; Additional file 1: Figure S4). Subgroup
analysis for trials that used iron 60 mg in the control
group was similar: systolic blood pressure difference
0.16 mmHg (95 % CI, –0.54 to 0.87; I2, 0 %), and diastolic
0.37 mmHg (95 % CI, –0.35 to 1.08; I2, 0 %; Additional file
1: Figure S3).
Cognitive function
The Bangladesh MINIMat, China, and Indonesia trials
all assessed subgroups of children: in Bangladesh, children
born in a 19-month period, at 7 months of age [48]; in
China, in the middle year of the trial up to 1 year of age
[49] and at 8.8 years [50]; and in Indonesia, in women
assigned to blood tests and whose children were born in a
6-month time period, at 3.5 years of age [37]. The Nepal
Sarlahi study administered cognitive, motor and executive
function tests at 7–9 years of age. Mean cognitive scores
were a little lower for the MMN group compared to iron,
folic acid and vitamin A (Universal Nonverbal Intelligence
Test score, –2.4; 95 % CI, –4.6 to –0.2). Results of motor
and executive function tests were mixed [51]. The
Bangladesh MINIMat and China trials found no difference
in motor or psychomotor scores [48, 49]. The Indonesia
trial found an increase in motor ability in an adjusted
Table 3 Mortality outcomes
Location Follow-up study Deaths in control groupa Livebirths in
control group
Deaths in
intervention groupa
Livebirths in
MMN group
Mortality differencea
MMN – control, per
1000 livebirths (95 % CI)
Bangladesh,
JiVitA
West et al. [26] 764
625 neonatal
139 at 29–180 days
14,142 741
626 neonatal
115 at 29–180 days
14,374 –2.5 (–8.1 to 3.1)b
Bangladesh,
MINIMat
Persson et al. [27] 33
23 neonatal
10 post-neonatal to
5 years
612 34
25 neonatal
9 post-neonatal to 5 years
595 3.2 (–22.6 to 29.0)
Burkina Faso Roberfroid
et al. [35]
45
7 neonatal
38 post-neonatal
to 30 months
644 55
11 neonatal
44 post-neonatal to
30 months
650 14.7 (–14.3 to 43.8)
Chinac Wang et al. [41] 16
16 neonatal
0 in children born
in 2004
1499 20
18 neonatal
2 in children born in 2004
1469 6.10 (–3.9 to 17.3)b
Guinea Bissau Andersen et al. [36] 57
25 neonatal
9 at 29–91 days
10 at 92–365 days
13 at 366–730 days
519 65
29 neonatal
6 at 29–91 days
21 at 92–365 days
9 at 366–730 days
528 13.3 (–25.8 to 52.4)
Indonesiac Prado et al. [37] 580 infant
17 in subsample
14,053 490 infant
12 in subsample
14,373 –13.2 (–33.4 to 7.1)b
Mexicoc Ramakrishnan
et al. [38]
7
6 early deaths
1 in control group of
childhood randomisation
460 4
4 early deaths
456 –10.30 (–29.30 to 6.60)
Nepal Janakpur Devakumar
et al. [39]
22
12 neonatal
6 post-neonatal
4 at 1–8 years
564 23
17 neonatal
4 post-neonatal
2 at 1–8 years
567 1.6 (–21.2 to 24.3)
Nepal Sarlahi Christian et al. [40] 54
34 before 91 days
20 at 91 days to 7 years
773 81
52 before 91 days
29 at 91 days to 7 years
872 23.0 (–5.2 to 51.3)b
aMortality figures given for the most recent follow-up. In the case of the Bangladesh MINIMat study, this was the trial paper
bThe analysis accounts for clustering in relevant trials. Design effects of 1.15, 1.20 and 1.20 were predicted in the Bangladesh JiVitA, Indonesia and Nepal Sarlahi
trials, respectively [26, 29, 34]; the China trial did not report a figure and we used a design effect of 1.20
cThe follow-up report described a subgroup of children; confidence intervals were created using a simulation approach, as described in more detail in the
methods section
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analysis expressed as a fraction of the variation of the
score (0.19; 95 % CI, 0.02 to 0.37) [37]. The Bangladesh
MINIMat follow-up found no difference in problem
solving or behaviour [48]. In the China trial, there were
no differences at 3 or 6 months, but age-adjusted scores at
1 year were higher for mental development in the MMN
supplementation group (1.20 points; 95 % CI, 0.32 to 2.08:
equivalent to about 6 days of age) [49]. At 8.8 years of age,
there were no differences in cognitive scores compared to
folic acid or to iron and folic acid groups [50]. The
Indonesia trial follow-up found no difference in visuospatial
and visual attention, executive functioning, language ability,
or socioemotional development [37].
For completeness, we mention stratified analyses. In
the Bangladesh MINIMat trial, stratification by maternal
BMI, combining the early and usual food groups together,
showed an increase in Psychomotor Development Index
in children whose mothers had been allocated to MMN
supplements and had BMI < 18.5 kg/m2 (0.22 z scores;
0.01 to 0.42; interaction term, P = 0.05) [48]. In Indonesia,
MMN supplementation was associated with greater motor
ability (β = 0.35 z scores; 95 % CI, 0.01 to 0.69, interaction
term, P = 0.04) and visual attention/spatial ability (β = 0.35;
95 % CI, 0.08 to 0.63, interaction term, P = 0.01) in chil-
dren of undernourished mothers (MUAC, < 23.5 cm).
These differences were equivalent to approximately
5 months of age [37].
Respiratory
The Nepal Janakpur trial investigated lung function at
8.5 years of age. Spirometry data were obtained from 836
children, with 793 (95 %) achieving optimal results using
American Thoracic Society/European Respiratory Society
guidelines [55]. No difference in lung function was found
between allocation groups: forced expiratory volume in
the first second, –0.01 L (95 % CI, –0.04 to 0.02 L); forced
vital capacity, –0.01 L (95 % CI, –0.04 to 0.02 L) [52].
Assessment of bias
Trials
The trials were considered high quality and bias was not
thought to be important. There was potential selection
bias in the Guinea-Bissau trial as a result of inadequately
concealed allocation [24], and potential attrition bias for
the Nepal Janakpur and Mexico trials, in which exclusions
prior to randomization were not reported [25, 30].
Follow-up reports
The trials were powered on the primary outcomes of
gestational age and birthweight (and mortality, in the
Fig. 1 Forest plot showing mortality rate per 1000 livebirths (meta-analysis using a random effects model)
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Table 4 Anthropometry, body composition and cardiovascular results
Follow-up
study
Weight
difference (z
scores)
% Underweight
(< –2 z scores)
Height
difference (z
scores)
% Stunted
(< –2 z scores)
Weight-for-
height/length
or BMI for age
% Wasted
or low BMI
(< –2 z
scores)
Body
composition
and skin fold
thickness
Body
circumferences
Blood pressure Other
Bangladesh
MINIMat
Khan et al. [42]
Anthroa
Calculated
difference: 0
(–0.114 to
0.114)
Calculated
difference: –
0.01 (–0.13 to
0.11)
4.8 % (0.8–8.9)
more stunting
across all
measurements
Calculated
difference: Wt-
for-ht z score,
0.01 (–0.09 to
0.11)
Khan et al. [45]
Body compa
Lean mass,
0.000 kg
(–0.123 to
0.125 kg); fat
mass, 0.001 kg
(–0.058 to
0.061 kg); no
difference in
biceps, triceps,
subscap or
suprailiac
skinfold
thicknesses
Calculated
difference:
head, 0.02 cm
(–0.20 to 0.24)
MUAC, 0.11 cm
(–0.04 to
0.26 cm)
Hawkesworth
et al. [46]
Compared to
30 mg iron
control adjusted
for iron
intervention
dummy and
food
intervention
variables:
Systolic, 0.05
(–0.71 to 0.81);
Diastolic, 0.55
(–0.10 to 1.20)
No difference in
kidney volumes
compared to
30 mg iron
Burkina
Faso
Roberfroid
et al. [35]
0.13 (–0.01
to 0.27)b
Hazard ratio in
1st year of life
0.84 (0.70, 1.02) c
–0.02 (–0.18 to
0.14)b Length
for age was
significantly
higher in the
first year, but
this disappeared
by 30 months
Hazard ratio in
1st year of life,
0.73 (0.60–0.87)c
0.20 (0.06–0.34)b
Wt-for-ht was
lower initially
but higher in
MMN from≥
10 months
Hazard ratio
in 1st year
of life, 1.10
(0.90–1.35)c
MUAC for age z,
0.18 (–2.93 to
3.29)b
China Wang
et al. [41]
Pooled (1–
30 months)
adjusted
difference:
0.03 (–0.05
to 0.10)d
Pooled (1-30
months)
adjusted. OR
0.95 (0.71, 1.29) d
Pooled (1–30
months)
adjusted
difference, 0.02
(–0.07 to 0.10)d
Pooled (1–30
months)
adjusted; OR,
0.82 (0.63–1.07)d
Pooled wt-for-
length (1–30
months)
adjusted differ
ence, 0.03
(–0.05 to 0.11)d
Pooled wt-
for-length
(1–30
months)
adjusted; OR,
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Table 4 Anthropometry, body composition and cardiovascular results (Continued)
0.89 (0.58–
1.36)d
Mexico Ramakrishnan
et al. [38]
Calculated
difference: –
0.1 (–0.34
to 0.14)
Calculated
difference: 0.2
(–0.08 to 0.48)
Calculated
difference:
Wt-for-ht –0.2
(–0.42 to 0.02)
Calculated
difference:
head, 0.2 cm
(–0.42 to 0.82)
Nepal
Janakpur
Vaidya et al. [43] 0.14 (0.00–
0.27)
37.8 % in
control, 36.6 %
in MMN
0.08 (–0.06 to
0.22)
60 % in
control, 56.7 %
in MMN
Wt-for-ht 0.12
(–0.02 to 0.26)
5.5 % in
control,
6.3 % in
MMN
Triceps,
0.20 mm (0.00–
0.40 mm)
Head, 0.24 cm
(0.06–0.43 cm);
MUAC, 0.24 cm
(0.11–0.37 cm)
Systolic,
–2.5 mmHg
(0.47–
4.55 mmHg);
Diastolic,
–1.5 mmHg
(–3.1 to
0.4 mmHg)
Devakumar
et al. [39]
0.05 (–0.09
to 0.19)
Not recorded
by trial group
0.02 (–0.10 to
0.15)
Not recorded
by trial group
BMI for age
0.04 (–0.09
to 0.18)
Not
recorded by
trial group
Lean mass,
–0.05 kg (–0.43
to 0.34 kg); fat
mass, –0.07 kg
(–0.32 to
0.18 kg); no
difference in
biceps, triceps,
subscapular
and suprailiac
skinfold
thicknesses
Head, 0.18 cm
(–0.02 to 0.38);
MUAC, 0.04
(–0.15 to
0.23 cm)
Systolic,
0.02 mmHg
(–1.02 to
1.05 mmHg);
Diastolic,
0.13 mmHg
(–0.93 to
1.19 mmHg)
No difference in
kidney dimensions;
exclusion of
children with
chronic or major
illness made no
difference
Nepal
Sarlahi
Stewart
et al. [44]
Calculated
difference:
–0.04 (95 %
CI, –0.15 to
0.07)e
Calculated
difference: 0.3 %
(95 % CI, –5.4
to 6.0)e
Calculated
difference:
–0.02 (–0.13
to 0.09)e
Calculated
difference:
3.7 % (–2.0–9.4)e
BMI for age
calculated
difference: –
0.04 (–0.14
to 0.06)e
Triceps: FeFol
+ vit A,
5.84 mm;
MMN, 5.9 mm;
Subscap: MMN,
4.81 mm;
FeFol + vit A
4.75 mm
MUAC: FeFol +
vit A, 15.4 cm;
MMN, 15.4 cm
Stewart
et al. [47]
Waist: FeFol +
vita A, 51.27 cm;
MMN, 51.22 cm
Systolic: FeFol
+ vit A,
95.2 mmHg;
MMN,
95.5 mmHg;
calculated
difference,
0.29 mmHg
(95 % CI, –0.65
to 1.23)d
Diastolic: FeFol
+ vit A,
63.9 mmHg;
MMN,
64.4 mmHg;
Non-fasting
glucose: FeFol +
vit A,
3.91 mmol/L;
MMN, 3.86
mmol/L;
LDL: FeFol +
vit A,
1.89 mmol/L;
MMN, 1.84
mmol/L; HDL:
FeFol + vit A,
0.72 mmol/L;
MMN, 0.70
mmol/L; at risk
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Table 4 Anthropometry, body composition and cardiovascular results (Continued)
calculated
difference,
0.56 mmHg
(95 % CI, –0.38
to 1.50)d
for metabolic
syndrome:
FeFol + vit A,
12.2 %; MMN,
11.9 %
Results are unadjusted differences unless otherwise stated. Calculated differences use results given in the paper to calculate the difference (intervention – control) in outcome and confidence intervals
HDL high density lipoprotein, LDL low density lipoprotein, FeFol iron and folic acid, MMN multiple micronutrient supplement
aComparisons were made with the 60 mg iron, 400 μg folic acid group and “usual” food supplementation
bParity, gestation, age at measurement, age at delivery, malaria treatment, health centre
cMalaria, health centre, parity, gestational age
dMixed linear models. Fixed effects: treatment, age, gender, birth weight, preterm, parity, feed methods, time of stay at outdoor, illness or health in last month before the interview, mother’s height, educational level,
occupation, number of supplement tablets consumed, and family socioeconomic status; random effects: village and individual subject
eWe have adjusted for cluster randomized controlled trial, assuming a design effect of 1.20
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case of the Bangladesh JiVitA Indonesia trials) [29].
Follow-up reports described power or sample size calcu-
lations before data collection, with the exception of the
Bangladesh MINIMat (cardiovascular) [46], Burkina Faso
(anthropometry) [35] and Nepal Sarlahi (anthropometry
and cardiovascular reports) follow-up publications [44,
47]. There was little statistical heterogeneity, with I2
values low for primary analyses (0–8 %). Some clinical
heterogeneity was present as participants were from dif-
ferent countries and ages of follow-up varied. The inter-
vention was the same in most cases, but (as described
above) the Bangladesh JiVitA, Mexico and Nepal Sarlahi
trials used slightly different multiple micronutrient for-
mulations, and the Bangladesh JiVitA, Indonesia, Mexico
and Nepal Sarlahi trials used different controls. Although
choice of outcomes varied from one report to another,
similar methods were used to assess similar outcomes.
Selection bias
Primarily a result of inadequate randomisation and allo-
cation concealment, this has been covered in the 2015
Cochrane assessment [20]. An additional potential source
of bias is selection of trials from the Cochrane review that
did not show an increase in birthweight associated with
MMN supplementation. The Cochrane review included
14 trials in its analysis of SGA. Of the five not considered
here [56–60], one showed a significant reduction in SGA
(Fawzi et al. [57], Tanzania; RR, 0.79; 95 % CI, 0.70–0.89).
Supplement composition was substantially different in this
trial, which compared a supplement containing eight vita-
mins and no minerals with a 60 mg iron and 250 μg folic
acid control [57]. Meta-analysis of the trials included in
our review showed an increase in birthweight of 30.2 g
(95 % CI, 14.1 to 46.3), which is similar in magnitude to
that found in previous meta-analyses [11, 61–63]. Simi-
larly, three of the 11 trials included in the meta-analysis of
neonatal mortality did not conduct follow-up studies.
None of these trials showed a reduction in neonatal mor-
tality. Meta-analysis of neonatal mortality rate for included
trials produced an RR of 1.01 (95 % CI, 0.90 to 1.16).
Performance and detection bias
Participants and data collectors in all follow-up reports
remained blind to allocation, with the exception of Guinea-
Bissau, where this was not mentioned explicitly in the
report.
Attrition bias
While all reports described loss to follow-up (Table 2),
attrition bias was relatively small (0–29 %), except in the
Mexico trial, in which just over half the children were
seen at 24 months. The largest group lost were too old
(>3 months) at the start of the follow-up. Excluding this
group, follow-up rates were similar to those of the other
reports. No important differences in loss to follow-up
Fig. 2 Forest plot showing weight-for-age (meta-analysis using a random effects model)
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between allocation groups were reported, with the ex-
ception of China at 9 years, where study groups differed
by school type, recent respiratory tract infection, mother’s
occupation (farmer or other) and father’s level of educa-
tion. These biases work in opposite directions and were
accounted for in the analyses [50]. Where recorded, differ-
ences between children retained and lost to follow-up
were small. Children lost to follow-up tended to have
mothers with more education (Bangladesh MINIMat,
Nepal Janakpur, Mexico and Nepal Sarlahi), lower parity
and younger age (Bangladesh MINIMat and Mexico),
and were more likely to live in an urban location (Nepal
Janakpur), have differences in ethnicity and assets (Nepal
Sarlahi), and lower birthweight and shorter gestation
(Bangladesh MINIMat). Maternal age, weight, height and
parity also differed in Guinea-Bissau, but the directions of
these effects were not reported. Although most reports
did not enumerate them, losses for individual outcomes
also occurred: (>20 % loss to measurement) kidney vol-
ume and function in the Bangladesh MINIMat trial, body
composition in the Nepal Janakpur trial, and fasting glu-
cose, insulin and homeostasis model assessment in the
Nepal Sarlahi trial.
Reporting bias
We could not make a definitive assessment of reporting
bias as follow-up protocols were unpublished, but funnel
plots for mortality, HAZ, WAZ and head circumference,
using results from the most recent follow-up report, did
not suggest publication bias for the primary outcomes
(Additional file 1: Figure S5).
Discussion
We found 20 follow-up reports for nine trials, covering
a range of health outcomes. Nine studies reported on
mortality, six on weight, six on height, and four on cog-
nitive function, but there were few reports of other out-
comes. Our hypothesis was not confirmed – we found
no evidence that antenatal MMN supplementation, com-
pared with iron and folic acid supplementation, led to
improved survival, improved growth, lower blood pres-
sure, or improved lung function in childhood. Potential
improvements in cognitive outcomes were observed, but
these were small and inconsistent and tended to be seen
in subgroups.
Quality of trials and limitations of the review
The trials had low risks of bias and were generally
considered of high-quality [20]. The degree of loss to
follow-up was not substantial, although in some cases
only subgroups were followed up. Differential loss to
follow-up between intervention and control groups
did not appear to be an issue, and neither did selective
publication, as most trials reported null findings. The
evidence on antenatal MMN supplementation comes
from a large sample and a substantial number of trials,
Fig. 3 Forest plot showing height-for-age (meta-analysis using a random effects model)
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many of which were coordinated. The trials considered
here were spread geographically, although 13 of the 20
follow-up reports were from South Asia, which may have
affected generalizability. Differences between the Nepal
and Bangladesh reports emphasize the fact that variation
can occur within similar populations.
The main limitation was that not all trials had published
reports on follow-up. We cannot be certain whether a se-
lection bias exists, but we found no indication of this.
Follow-up reports have published null findings, rather
than positive ones. If a publication bias does exist, it would
not work in this direction. None of the trials had initially
set out to observe childhood outcomes. While power cal-
culations were performed prior to most follow-ups, trials
were powered on birth outcomes and larger sample sizes
may be required to detect small differences in childhood.
Functional outcomes were measured at different ages and
may not be comparable. We attempted to address this by
using z scores, adjusted for age and sex, as primary out-
comes. This was not always possible and limits inferences
from the head circumference and blood pressure findings.
We tried to make comparisons as similar as possible, but
our findings could be vitiated by slightly different MMN
and control supplement compositions in some trials.
Mortality
Antenatal MMN supplementation was initially hypothe-
sized to reduce mortality, but increases in neonatal mor-
tality were suspected in some trials [64]. A meta-analysis
did not find a difference in neonatal mortality overall,
but raised concerns about increased early neonatal
mortality (OR, 1.23; 95 % CI, 0.95 to 1.59). The 2015
Cochrane review found a reduction in stillbirths (0.91;
95 % CI, 0.85 to 0.98, n = 15), and no effect on perinatal
(0.97; 95 % CI, 0.84 to 1.12, n = 12) or neonatal mortality
(0.98; 95 % CI, 0.90 to 1.07, n = 11) [20]. The reduction
in stillbirths is interesting and potentially important [65].
It depended on the analytical weighting (57 %) of the
study by West et al. [26] and the use of a fixed effects
model, and requires confirmation. A suggestion that
MMN supplementation would prevent 43,715 annual
child deaths (with 90 % coverage in 34 countries most in
need) followed from the Lives Saved Tool model, based on
evidence that reductions in the prevalence of SGA are as-
sociated with reduced stunting and subsequent child sur-
vival [12]. Our analyses did not identify evidence of an
effect on child mortality and do not support the assump-
tions made in the Lives Saved Tool.
Anthropometry and body composition
Overall, follow-up reports did not show differences in
anthropometry or body composition. A transient im-
provement was seen in early life in the Burkina Faso and
Nepal Janakpur trials, and there was a suggestion of in-
creased stunting in Bangladesh, but these findings were
not replicated in other reports. There was a consistent
lack of effect on height. It is conceivable that MMN sup-
plementation could have physiological effects that are
not manifest in substantial anthropometric change. For
example, transient greater weight in early childhood could
have long-term benefits, even if not apparent in the
short-term.
Fig. 4 Forest plot showing head circumference (meta-analysis using a random effects model)
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Cognitive development
Small improvements in mental development were seen
in China [49] at 1 year but not at 9 years, cognitive score
was lower in Nepal Sarlahi [51], and the Bangladesh
MINIMat and Indonesia trials found improvements in
subgroups of mothers with poorer nutritional status only
[37, 48]. Considering the number and range of tests con-
ducted, antenatal MMN supplements did not appear to
lead to a consistent cognitive benefit. When found, dif-
ferences tended to be small and three of the five reports
involved children under 4 years, in whom cognitive tests
are less reliable than in older children. Further assessment
of these cohorts is warranted.
Other outcomes
Comparison of follow-ups did not confirm the impression
of transiently lower systolic blood pressure at 2.5 years in
the Nepal Janakpur trial, or of improved lung function in
children seen in a similar trial of vitamin A supplementa-
tion from Nepal Sarlahi [66]. Only one trial considered
other cardiovascular risk markers and found no effects.
Inferences
On the basis of the reports we have reviewed, current
evidence does not support changing the recommenda-
tion for routine antenatal supplementation from iron
and folic acid to MMN formulations. It is possible –
even probable – that the trial populations differed in
their patterns of micronutrient deficiency. There was lit-
tle evidence to suggest that this influenced the general
findings. Although there is consistent evidence that
antenatal MMN supplementation increases birth weight,
none of the studies demonstrated convincingly that it
benefitted offspring in terms of functional or health out-
comes, and the directions and magnitudes of effect were
similar for mortality and anthropometric outcomes
across the study sites. The findings of the Cochrane re-
view on which recent advocacy for routine antenatal
MMN supplementation are based are supported by other
meta-analyses that have shown an increase in mean birth-
weight of 22–54 g and corresponding reductions in low
birthweight and SGA. As may be expected, the erosion
over time of anthropometric differences observed at birth
suggests that infants of women who received antenatal
MMN supplements lost an advantage over the first few
years. This could be the result of numerous environmental
stresses over postnatal life. No other changes in anthro-
pometry, gestation or mortality were found [11, 20, 22,
61–63]. However, improvement in later health outcomes
does not necessarily depend on supplementation causing
an increase in birthweight (or organ size). The mecha-
nisms of action are likely to be multifactorial and follow-
up reports suggest other mechanisms such as the effect of
vitamin A on regulation of fetal lung growth, branching
and alveolarisation [67, 68]. We also cannot rule out ef-
fects emerging later in life or in the next generation. From
an evolutionary perspective, supplementing mothers could
potentially benefit the woman herself, the index baby, or
future offspring. Antenatal micronutrient supplementation
has a role in women with a deficiency-related illness, and
possibly in micronutrient deficiency itself, but population
supplementation may need to start earlier, either in the
first trimester or pre-conception, to include the period of
rapid organogenesis and genome-wide epigenetic changes
that follow fertilization, and be continued into childhood
[16, 69, 70]. The formulations of MMN tested may also not
be the optimum ones. We cannot rule out the possibility
that combinations other than the ones tested might have
positive outcomes. It is possible that additional micronutri-
ents, or different doses, might result in functional benefits.
The annual cost of MMN supplementation in pregnancy
(at 90 % coverage) in the 34 LMICs in which it would be
most useful is estimated at (International)$ 472 million
[12]. If, as our review suggests, initiating antenatal MMN
supplementation in early/mid-pregnancy does not lead to
the anticipated improvements in childhood function or
health – the main current justification for recommending
it – the opportunity costs to other programmes that do
lead to improvements will need to be considered.
Implications for future research
More evidence is needed, especially on cognitive devel-
opment, cardiovascular risk markers and lung function,
to adequately appraise the long-term effects of antenatal
MMN supplementation. We recommend follow-up
studies in more of the MMN trials. Further research into
biological mechanisms by which an early advantage
could be attenuated will help in our understanding of
the intervention and in designing future trials.
Conclusions
In summary, our review of published follow-up reports
has not shown persisting effects of antenatal MMN sup-
plementation during childhood, compared with iron and
folic acid. Phenotypic and physiological differences may
arise later in life or as more research is conducted, but
the current evidence base is insufficient to support routine
MMN supplementation in pregnancy at a population level
in low- and middle-income countries.
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